Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma

Steven Orlov, David Orlov, Michael Shaytzag, Mark Dowar, Vafa Tabatabaie, Philip Dwek, Jonathan Yip, Cindy Hu, Jeremy L. Freeman, Paul G. Walfish

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. Though age and primary tumor size predict cancer-specific survival in well-differentiated thyroid carcinoma (WDTC), their influence on residual/recurrent disease has not been elucidated. Methods. In a retrospective study, residual/recurrent disease was defined by the surrogate outcome of positive (≥2 lg/L) follow-up stimulated thyroglobulin after surgery and radioactive remnant ablation. Age, primary tumor size, and clinical staging systems were examined in the context of stimulated thyroglobulin outcome. Results. A total of 246 patients were followed up for a mean of 5.8 years. No significant difference in age (t(239) = 0.61, p > .05) or tumor size (t(237) = 0.16, p > .05) was found among patients with positive follow-up stimulated thyroglobulin compared with those with negative results. pTNM staging failed to demonstrate significant, stage-dependent increase in the percentage of patients with positive stimulated thyroglobulin, χ2(2, N = 229) = 0.17, p > .05, unlike staging based solely on surgical pathology, χ2(2, N = 241) = 34.97, p < .001. Conclusion. Age, primary tumor size, and pTNM staging do not predict risk for residual/recurrent WDTC, whereas extrathyroidal extension at initial surgery is predictive.

Original languageEnglish (US)
Pages (from-to)782-788
Number of pages7
JournalHead and Neck
Volume31
Issue number6
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Thyroid Neoplasms
Thyroglobulin
Neoplasms
Surgical Pathology
Retrospective Studies
Survival

Keywords

  • Clinical predictors
  • DeGroot staging
  • Patient age
  • Primary tumor size
  • pTNM staging
  • Thyroid carcinoma

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. / Orlov, Steven; Orlov, David; Shaytzag, Michael; Dowar, Mark; Tabatabaie, Vafa; Dwek, Philip; Yip, Jonathan; Hu, Cindy; Freeman, Jeremy L.; Walfish, Paul G.

In: Head and Neck, Vol. 31, No. 6, 06.2009, p. 782-788.

Research output: Contribution to journalArticle

Orlov, S, Orlov, D, Shaytzag, M, Dowar, M, Tabatabaie, V, Dwek, P, Yip, J, Hu, C, Freeman, JL & Walfish, PG 2009, 'Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma', Head and Neck, vol. 31, no. 6, pp. 782-788. https://doi.org/10.1002/hed.21020
Orlov, Steven ; Orlov, David ; Shaytzag, Michael ; Dowar, Mark ; Tabatabaie, Vafa ; Dwek, Philip ; Yip, Jonathan ; Hu, Cindy ; Freeman, Jeremy L. ; Walfish, Paul G. / Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. In: Head and Neck. 2009 ; Vol. 31, No. 6. pp. 782-788.
@article{1fe02c92df924854886ee3d3c8d4a912,
title = "Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma",
abstract = "Background. Though age and primary tumor size predict cancer-specific survival in well-differentiated thyroid carcinoma (WDTC), their influence on residual/recurrent disease has not been elucidated. Methods. In a retrospective study, residual/recurrent disease was defined by the surrogate outcome of positive (≥2 lg/L) follow-up stimulated thyroglobulin after surgery and radioactive remnant ablation. Age, primary tumor size, and clinical staging systems were examined in the context of stimulated thyroglobulin outcome. Results. A total of 246 patients were followed up for a mean of 5.8 years. No significant difference in age (t(239) = 0.61, p > .05) or tumor size (t(237) = 0.16, p > .05) was found among patients with positive follow-up stimulated thyroglobulin compared with those with negative results. pTNM staging failed to demonstrate significant, stage-dependent increase in the percentage of patients with positive stimulated thyroglobulin, χ2(2, N = 229) = 0.17, p > .05, unlike staging based solely on surgical pathology, χ2(2, N = 241) = 34.97, p < .001. Conclusion. Age, primary tumor size, and pTNM staging do not predict risk for residual/recurrent WDTC, whereas extrathyroidal extension at initial surgery is predictive.",
keywords = "Clinical predictors, DeGroot staging, Patient age, Primary tumor size, pTNM staging, Thyroid carcinoma",
author = "Steven Orlov and David Orlov and Michael Shaytzag and Mark Dowar and Vafa Tabatabaie and Philip Dwek and Jonathan Yip and Cindy Hu and Freeman, {Jeremy L.} and Walfish, {Paul G.}",
year = "2009",
month = "6",
doi = "10.1002/hed.21020",
language = "English (US)",
volume = "31",
pages = "782--788",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma

AU - Orlov, Steven

AU - Orlov, David

AU - Shaytzag, Michael

AU - Dowar, Mark

AU - Tabatabaie, Vafa

AU - Dwek, Philip

AU - Yip, Jonathan

AU - Hu, Cindy

AU - Freeman, Jeremy L.

AU - Walfish, Paul G.

PY - 2009/6

Y1 - 2009/6

N2 - Background. Though age and primary tumor size predict cancer-specific survival in well-differentiated thyroid carcinoma (WDTC), their influence on residual/recurrent disease has not been elucidated. Methods. In a retrospective study, residual/recurrent disease was defined by the surrogate outcome of positive (≥2 lg/L) follow-up stimulated thyroglobulin after surgery and radioactive remnant ablation. Age, primary tumor size, and clinical staging systems were examined in the context of stimulated thyroglobulin outcome. Results. A total of 246 patients were followed up for a mean of 5.8 years. No significant difference in age (t(239) = 0.61, p > .05) or tumor size (t(237) = 0.16, p > .05) was found among patients with positive follow-up stimulated thyroglobulin compared with those with negative results. pTNM staging failed to demonstrate significant, stage-dependent increase in the percentage of patients with positive stimulated thyroglobulin, χ2(2, N = 229) = 0.17, p > .05, unlike staging based solely on surgical pathology, χ2(2, N = 241) = 34.97, p < .001. Conclusion. Age, primary tumor size, and pTNM staging do not predict risk for residual/recurrent WDTC, whereas extrathyroidal extension at initial surgery is predictive.

AB - Background. Though age and primary tumor size predict cancer-specific survival in well-differentiated thyroid carcinoma (WDTC), their influence on residual/recurrent disease has not been elucidated. Methods. In a retrospective study, residual/recurrent disease was defined by the surrogate outcome of positive (≥2 lg/L) follow-up stimulated thyroglobulin after surgery and radioactive remnant ablation. Age, primary tumor size, and clinical staging systems were examined in the context of stimulated thyroglobulin outcome. Results. A total of 246 patients were followed up for a mean of 5.8 years. No significant difference in age (t(239) = 0.61, p > .05) or tumor size (t(237) = 0.16, p > .05) was found among patients with positive follow-up stimulated thyroglobulin compared with those with negative results. pTNM staging failed to demonstrate significant, stage-dependent increase in the percentage of patients with positive stimulated thyroglobulin, χ2(2, N = 229) = 0.17, p > .05, unlike staging based solely on surgical pathology, χ2(2, N = 241) = 34.97, p < .001. Conclusion. Age, primary tumor size, and pTNM staging do not predict risk for residual/recurrent WDTC, whereas extrathyroidal extension at initial surgery is predictive.

KW - Clinical predictors

KW - DeGroot staging

KW - Patient age

KW - Primary tumor size

KW - pTNM staging

KW - Thyroid carcinoma

UR - http://www.scopus.com/inward/record.url?scp=67049156007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049156007&partnerID=8YFLogxK

U2 - 10.1002/hed.21020

DO - 10.1002/hed.21020

M3 - Article

C2 - 19260133

AN - SCOPUS:67049156007

VL - 31

SP - 782

EP - 788

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 6

ER -